The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background...

Area of Science:

• Pediatric Oncology
• Cancer Research
• Clinical Trials

Background:

• Rhabdomyosarcoma (RMS) is a rare pediatric cancer.
• Long-term data from large patient cohorts are crucial for refining treatment protocols.

Purpose of the Study:

• To analyze outcomes and derive critical lessons from a large cohort of 4292 rhabdomyosarcoma patients treated between 1972 and 1997.
• To inform current and future risk-based management strategies for pediatric RMS.

Main Methods:

• Review of pathologic materials and treatment records for 4292 untreated patients under 21 years old.
• Assessment of treatment compliance, response, and relapse status.

Main Results:

• Five-year survival increased from 55% to 71% during the study period.
• Disease extent at diagnosis significantly impacts prognosis; re-excision of incomplete tumor removal is beneficial if function is preserved.
• Organ-sparing approaches are feasible for eye, vagina, and bladder.
• Conventional once-daily radiation therapy (XRT) is as effective as hyperfractionated XRT for local control.
• Localized XRT and chemotherapy can cure non-metastatic cranial parameningeal sarcoma without whole-brain XRT or intrathecal drugs.
• Addition of newer agents to VAC chemotherapy did not significantly improve survival for patients with gross residual or metastatic disease.

Conclusions:

• Treatment strategies for rhabdomyosarcoma have evolved, leading to improved survival.
• Risk-stratified management, informed by disease extent and specific tumor characteristics, is essential.
• Ongoing research is investigating novel agents like topotecan and irinotecan for high-risk recurrence.